AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Serina Therapeutics Soars 28.55% on FDA Trial Design Approval
Generated by AI AgentBefore the Bell
Tuesday, Aug 26, 2025 4:20 am ET1min read
Aime SummaryOn August 26, 2025,
experienced a significant surge in its stock price, rising by 28.55% in pre-market trading.Serina Therapeutics recently received positive feedback from the FDA regarding the registrational trial design of its drug candidate SER-252 for advanced Parkinson's disease. This feedback supports the company's plan to advance SER-252 into a registrational clinical program under the 505(b)(2) NDA pathway. The FDA's backing has been a key driver for the stock's recent gains, as retail traders anticipate further advancements in the drug's development.
Serina Therapeutics has also announced plans to file an Investigational New Drug (IND) application for SER-252 in the fourth quarter of 2025. This move is part of the company's strategic efforts to accelerate the development of its novel Parkinson's therapy. The IND filing is a crucial step towards initiating clinical trials and bringing SER-252 closer to market.
Before the Bell
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Rezolve AI (NASDAQ: RZLV) Rides AI Wave to 12.26% Surge on Strategic Alliances
Dec.05 2025
Build-A-Bear (BBW) Plunges 15.54% as Tariff Woes and Analyst Downgrade Spur Sell-Off
Dec.05 2025
Maravai Biosciences (MRVI) Shares Surge 5.41% as Life Sciences Momentum and Fiscal 2026 Outlook Drive Optimism
Dec.05 2025
SES AI Shares Soar 14.5% on AI Sector Optimism, Strategic Positioning
Dec.05 2025
ORCL Shares Surge 3.18% on AI-Driven Optimism Ahead of Earnings Report
Dec.05 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet